Preclinical Pharmacokinetics in Tumors and Normal Tissues of the Antigene PNA Oligonucleotide MYCN-Inhibitor BGA002.

Autor: Scardovi AL; R&D Department, BIOGENERA SpA, Bologna, Italy., Bartolucci D; R&D Department, BIOGENERA SpA, Bologna, Italy., Montemurro L; AGEOP Ricerca OdV, IRCCS S. Orsola Hospital, Pediatric Oncology and Hematology Unit, Bologna, Italy., Bortolotti S; R&D Department, BIOGENERA SpA, Bologna, Italy., Angelucci S; R&D Department, BIOGENERA SpA, Bologna, Italy., Amadesi C; R&D Department, BIOGENERA SpA, Bologna, Italy., Nieddu G; R&D Department, BIOGENERA SpA, Bologna, Italy., Oosterholt S; Clinical Pharmacology & Therapeutics Group, University College London, London, United Kingdom., Cerisoli L; R&D Department, BIOGENERA SpA, Bologna, Italy., Della Pasqua O; Clinical Pharmacology & Therapeutics Group, University College London, London, United Kingdom., Hrelia P; Department of Pharmacy and Biotechnologies, University of Bologna, Bologna, Italy., Tonelli R; Department of Pharmacy and Biotechnologies, University of Bologna, Bologna, Italy.

Publikováno v: Nucleic acid therapeutics [Nucleic Acid Ther] 2024 Aug; Vol. 34 (4), pp. 173-187. Date of Electronic Publication: 2024 Jul 03.

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.

Autor: Lampis S; R&D Department, BIOGENERA SpA, Bologna, Italy., Raieli S; R&D Department, BIOGENERA SpA, Bologna, Italy., Montemurro L; Pediatric Unit, S. Orsola IRCCS, University of Bologna, Bologna, Italy., Bartolucci D; R&D Department, BIOGENERA SpA, Bologna, Italy., Amadesi C; R&D Department, BIOGENERA SpA, Bologna, Italy., Bortolotti S; R&D Department, BIOGENERA SpA, Bologna, Italy., Angelucci S; R&D Department, BIOGENERA SpA, Bologna, Italy., Scardovi AL; R&D Department, BIOGENERA SpA, Bologna, Italy., Nieddu G; R&D Department, BIOGENERA SpA, Bologna, Italy., Cerisoli L; R&D Department, BIOGENERA SpA, Bologna, Italy., Paganelli F; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.; CNR Institute of Molecular Genetics 'Luigi Luca Cavalli-Sforza', Unit of Bologna, Bologna, Italy., Valente S; Biotechnology and Methods in Laboratory Medicine, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy., Fischer M; Department of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Medical Faculty, Cologne, Germany; and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany., Martelli AM; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy., Pasquinelli G; Biotechnology and Methods in Laboratory Medicine, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.; Subcellular nephro-vascular diagnostic program, Pathology Unit S. Orsola IRCCS, University of Bologna, Bologna, Italy., Pession A; Pediatric Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Hrelia P; Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy., Tonelli R; Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy. roberto.tonelli@unibo.it.

Publikováno v: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2022 Apr 30; Vol. 41 (1), pp. 160. Date of Electronic Publication: 2022 Apr 30.

MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma.

Autor: Raieli S; R&D Department, BIOGENERA SpA, Bologna, Italy., Di Renzo D; Department of Pharmacy and Biotechnologies, University of Bologna, Bologna, Italy., Lampis S; R&D Department, BIOGENERA SpA, Bologna, Italy., Amadesi C; R&D Department, BIOGENERA SpA, Bologna, Italy., Montemurro L; Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Pession A; Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Hrelia P; Department of Pharmacy and Biotechnologies, University of Bologna, Bologna, Italy., Fischer M; Department of Experimental Pediatric Oncology, Medical Faculty, University Children's Hospital of Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany., Tonelli R; Department of Pharmacy and Biotechnologies, University of Bologna, Bologna, Italy.

Publikováno v: Frontiers in oncology [Front Oncol] 2021 Feb 25; Vol. 11, pp. 625207. Date of Electronic Publication: 2021 Feb 25 (Print Publication: 2021).

Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells.

Autor: Maines, Lynn W.¹ (AUTHOR), Keller, Staci N.¹ (AUTHOR), Smith, Ryan A.¹ (AUTHOR), Schrecengost, Randy S.¹ (AUTHOR), Smith, Charles D.¹ (AUTHOR) cdsmith@apogee-biotech.com

Publikováno v: Cancers. May2024, Vol. 16 Issue 9, p1779. 17p.

Chlorogenic Acid Induced Neuroblastoma Cells Differentiation via the ACAT1-TPK1-PDH Pathway.

Autor: You, Shen¹ (AUTHOR) youshen@imm.ac.cn, Wang, Ming-Jin¹ (AUTHOR) wangmingjin@imm.ac.cn, Hou, Zhen-Yan¹ (AUTHOR) houzhenyan@imm.ac.cn, Wang, Wei-Da¹ (AUTHOR) wangweida@imm.ac.cn, Du, Ting-Ting^1,2 (AUTHOR) ninadu@imm.ac.cn, Xue, Ni-Na^1,2 (AUTHOR) angelnina@imm.ac.cn, Ji, Ming^1,3 (AUTHOR) jiming@imm.ac.cn, Chen, Xiao-Guang^1,2 (AUTHOR) jiming@imm.ac.cn

Publikováno v: Pharmaceuticals (14248247). Jun2023, Vol. 16 Issue 6, p877. 15p.